These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 22146443)

  • 1. Efficient drug approval and monitoring must rely on sound regulatory science.
    Meagher EA; Fitzgerald GA
    Nat Med; 2011 Dec; 17(12):1535. PubMed ID: 22146443
    [No Abstract]   [Full Text] [Related]  

  • 2. Regulatory science and the role of the regulator in biomedical innovation.
    Honig PK; Huang SM
    Clin Pharmacol Ther; 2012 Mar; 91(3):347-52. PubMed ID: 22343804
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk versus risk: decision-making dilemmas of drug regulation in the United States and Germany.
    Daemmrich A; Krucken G
    Sci Cult (Lond); 2000 Dec; 9(4):505-34. PubMed ID: 15988846
    [No Abstract]   [Full Text] [Related]  

  • 4. Regulatory science as a bridge between science and society.
    Tominaga T; Asahina Y; Uyama Y; Kondo T
    Clin Pharmacol Ther; 2011 Jul; 90(1):29-31. PubMed ID: 21691273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory science as culture: contested two-dimensional values at the US FDA.
    Abraham J
    Sci Cult (Lond); 2002 Sep; 11(3):309-35. PubMed ID: 15971364
    [No Abstract]   [Full Text] [Related]  

  • 6. Perestroika in pharma: evolution or revolution in drug development?
    FitzGerald GA
    Mt Sinai J Med; 2010; 77(4):327-32. PubMed ID: 20687177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A regulatory perspective on in vitro diagnostics.
    Gottlieb S; Woodcock J
    Nat Biotechnol; 2006 Aug; 24(8):927-9. PubMed ID: 16900132
    [No Abstract]   [Full Text] [Related]  

  • 8. Advancing FDA's regulatory science through weight of evidence evaluations.
    Cormier JW
    J Contemp Health Law Policy; 2011; 28(1):1-22. PubMed ID: 22292318
    [No Abstract]   [Full Text] [Related]  

  • 9. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.
    Wang Y; Bhattaram AV; Jadhav PR; Lesko LJ; Madabushi R; Powell JR; Qiu W; Sun H; Yim DS; Zheng JJ; Gobburu JV
    J Clin Pharmacol; 2008 Feb; 48(2):146-56. PubMed ID: 18199891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Science, ethics and economics in FDA decision-making: the legal framework.
    Cooper RM
    Food Drug Law J; 2006; 61(4):799-803. PubMed ID: 17180773
    [No Abstract]   [Full Text] [Related]  

  • 11. America's other drug problem: how the drug industry distorts medicine and politics.
    Relman AS; Angell M
    New Repub; 2002 Dec; 227(25):27-41. PubMed ID: 12561803
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacometrics at FDA: evolution and impact on decisions.
    Powell JR; Gobburu JV
    Clin Pharmacol Ther; 2007 Jul; 82(1):97-102. PubMed ID: 17538553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA proposes "regulatory science" initiatives.
    Nurse Educ; 2011; 36(2):75. PubMed ID: 21330898
    [No Abstract]   [Full Text] [Related]  

  • 14. Institutional review boards and approval of new products without human subjects research.
    Maloney DM
    Hum Res Rep; 2002 Jul; 17(7):1-2. PubMed ID: 12731489
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA and EMEA pool scientific advice.
    Katsnelson A
    Nat Biotechnol; 2004 Dec; 22(12):1490-1. PubMed ID: 15583642
    [No Abstract]   [Full Text] [Related]  

  • 16. Shaking up the status quo: how AIDS activists have challenged drug development and approval procedures.
    Dunbar MM
    Food Drug Cosmet Law J; 1991 Sep; 46(5):673-706. PubMed ID: 11651380
    [No Abstract]   [Full Text] [Related]  

  • 17. Agency seeks approval of financial disclosure steps for researchers.
    Maloney DM
    Hum Res Rep; 2002 Mar; 17(3):1-2. PubMed ID: 12408150
    [No Abstract]   [Full Text] [Related]  

  • 18. Development of vaccines to meet public health needs: incentives and obstacles.
    Russell PK
    Risk; 1996; 7(3):239-52. PubMed ID: 11655077
    [No Abstract]   [Full Text] [Related]  

  • 19. Missing data issues at the FDA Center for Biologics Evaluation and Research.
    Scott JA; Hsu H
    J Biopharm Stat; 2011 Mar; 21(2):196-201. PubMed ID: 21390996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementing a successful clinical development program for female sexual dysfunctions (aka how to navigate a regulatory minefield).
    Simon JA
    Maturitas; 2011 Jun; 69(2):97-8. PubMed ID: 21497031
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.